Compounds for the treatment of metabolic disorders

Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Ketone doai

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C514S721000, C568S325000, C568S631000

Reexamination Certificate

active

07820721

ABSTRACT:
Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R1is alkyl having from 1 to 3 carbon atoms; R2is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R3and R4is hydrogen or hydroxy and the other is hydrogen; or R3and R4together are ═O; R5is hydrogen or alkyl having one, two, three, four or five carbon atoms; A is phenyl, unsubstituted or substituted by 1 or 2 groups selected from: halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; or cycloalkyl having from 3 to 6 ring carbon atoms wherein the cycloalkyl is unsubstituted or one or two ring carbons are independently mono-substituted by methyl or ethyl; or a 5 or 6 membered heteroaromatic ring having 1 or 2 ring heteroatoms selected from N, S and O and the heteroaromatic ring is covalently bound to the remainder of the compound of formula I by a ring carbon. Alternatively, the. agent can be a pharmaceutically acceptable salt of the compound of Formula I.

REFERENCES:
patent: 4350822 (1982-09-01), Albright et al.
patent: 6248765 (2001-06-01), Schwartz et al.
patent: 6858602 (2005-02-01), Sharma et al.
patent: 6916848 (2005-07-01), Sharma
patent: 6924314 (2005-08-01), Sharma et al.
patent: 6946491 (2005-09-01), Sharma et al.
patent: 7012071 (2006-03-01), Sharma et al.
patent: 7041659 (2006-05-01), Sharma
patent: 7045541 (2006-05-01), Sharma
patent: 7101910 (2006-09-01), Sharma
patent: 7329782 (2008-02-01), Sharma et al.
patent: 7361686 (2008-04-01), Hodge et al.
patent: 7442796 (2008-10-01), Sharma et al.
patent: 2002/0064847 (2002-05-01), Yamamoto et al.
patent: 2005/0090555 (2005-04-01), Sharma et al.
patent: 2006/0014784 (2006-01-01), Hodge et al.
patent: 2006/0035970 (2006-02-01), Hodge et al.
patent: 2006/0247309 (2006-11-01), Hodge et al.
patent: 2007/0105958 (2007-05-01), Sharma et al.
patent: 2007/0249696 (2007-10-01), Sharma et al.
patent: 2007/0249719 (2007-10-01), Sharma et al.
patent: 2007/0265322 (2007-11-01), Sharma et al.
patent: 2007/0282003 (2007-12-01), Sharma et al.
patent: 2008/0015209 (2008-01-01), Sharma et al.
patent: 2008/0015254 (2008-01-01), Sharma et al.
patent: 2008/0021109 (2008-01-01), Sharma et al.
patent: 2008/0027229 (2008-01-01), Hodge et al.
patent: 329464 (1989-08-01), None
patent: 03075368 (1990-06-01), None
patent: 1390580 (1975-04-01), None
patent: 91/19702 (1991-12-01), None
patent: 02/100341 (2002-12-01), None
patent: 2004/073611 (2004-09-01), None
patent: 2004/091486 (2004-10-01), None
Franke et. al., Helvetica Chimica Acta, 1975, Wiley-VCH, vol. 58, No. 1, pp. 293-296 (English abstract attached).
Bojarski, et al., “Gamma-Hydroxybutyric Acid (GHB) and its Chemical Modifications: A Review of the GHBergic System”, Polish Journal of Pharmacology, vol. 56, pp. 43-49, 2004.
Younis, et al., “The prevention of type 2 diabetes mellitus: recent advances”, QJ Med., vol. 97, pp. 451-455, 2004.
Goff, et al., “Prevention of Cardiovascular Disease in Persons with type 2 diabetes Mellitus: Current Knowledge and Rational for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial”, AM J Cardiol., 99(12A): S4-S20, 2007. (Abstract).
Knowler, et al., “Perspectives in Diabetes: Preventing Non-Insulin-Dependent Diabetes”, Diabetes, vol. 44, pp. 483-488, 1995.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,515.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,520.
Pending (as of Mar. 24, 2008) claims from U.S. Appl. No. 11/772,560.
Pending (as of Sep. 25, 2008) claims from U.S. Appl. No. 12/294,530.
Pending (as of Jul. 14, 2008) claims from U.S. Appl. No. 12/160,857.
Pending (as of Jul. 28, 2008) claims from U.S. Appl. No. 12/162,397.
Pending (as of May 7, 2008) claims from U.S. Appl. No. 12/092,932.
Pending (as of Aug. 18, 2008) claims from U.S. Appl. No. 12/160,808.
Pending (as of Aug. 13, 2008) claims from U.S. Appl. No. 12/279,247.
Pending (as of Jul. 14, 2008) claims from U.S. Appl. No. 12/160,858.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Compounds for the treatment of metabolic disorders does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds for the treatment of metabolic disorders, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds for the treatment of metabolic disorders will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-4174805

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.